Investment Analysts’ Recent Ratings Updates for Teladoc Health (TDOC)

Teladoc Health (NYSE: TDOC) has recently received a number of price target changes and ratings updates:

• 11/2/2026 – Teladoc Health had its price target raised by UBS Group from $6.50 to $9.00. They now have a “neutral” rating on the stock.
• 11/2/2026 – Teladoc Health had its price target raised by Oppenheimer from $7.00 to $10.00. They now have an “outperform” rating on the stock.
• 11/2/2026 – Teladoc Health was downgraded by Argus from “hold” to “sell”.
• 10/30/2026 – Teladoc Health had its price target raised by JPMorgan Chase & Co. from $8.00 to $10.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Teladoc Health had its price target raised by Stifel Nicolaus from $5.50 to $6.50. They now have a “hold” rating on the stock.
• 10/29/2026 – Teladoc Health had its “hold” rating reaffirmed by Needham & Company LLC.

Teladoc Health Price Performance

Shares of NYSE:TDOC traded up $0.30 on Tuesday, hitting $8.93. 6,105,841 shares of the company’s stock were exchanged, compared to its average volume of 5,121,503. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.89. The business’s 50 day simple moving average is $6.28 and its two-hundred day simple moving average is $6.48. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -10.38 and a beta of 2.14.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The firm had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. During the same period last year, the firm posted ($0.28) EPS. Teladoc Health’s revenue was down 3.4% on a year-over-year basis. Equities analysts forecast that Teladoc Health, Inc. will post -0.89 EPS for the current fiscal year.

Insider Activity at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.70% of the company’s stock.

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.